MX347570B - Compuestos triciclicos, composiciones que los comprenden y usos de los mismos. - Google Patents

Compuestos triciclicos, composiciones que los comprenden y usos de los mismos.

Info

Publication number
MX347570B
MX347570B MX2014005765A MX2014005765A MX347570B MX 347570 B MX347570 B MX 347570B MX 2014005765 A MX2014005765 A MX 2014005765A MX 2014005765 A MX2014005765 A MX 2014005765A MX 347570 B MX347570 B MX 347570B
Authority
MX
Mexico
Prior art keywords
compositions
tricyclic compounds
disease
overweight
disorder
Prior art date
Application number
MX2014005765A
Other languages
English (en)
Other versions
MX2014005765A (es
Inventor
Ben-Sasson Shmuel
Dagan Arie
Perles Sharon
Original Assignee
Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd filed Critical Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd
Publication of MX2014005765A publication Critical patent/MX2014005765A/es
Publication of MX347570B publication Critical patent/MX347570B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

Compuestos tricíclicos, composiciones y usos de los mismos en el tratamiento de al menos una enfermedad, trastorno o condición tal como, por ejemplo, obesidad, sobrepeso, distribución anormal de grasa, y cualquier condición o enfermedad asociada con los mismos.
MX2014005765A 2011-11-15 2012-11-15 Compuestos triciclicos, composiciones que los comprenden y usos de los mismos. MX347570B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161559964P 2011-11-15 2011-11-15
US201261603508P 2012-02-27 2012-02-27
PCT/IL2012/050461 WO2013072915A1 (en) 2011-11-15 2012-11-15 Tricyclic compounds, compositions comprising them and uses thereof

Publications (2)

Publication Number Publication Date
MX2014005765A MX2014005765A (es) 2015-09-23
MX347570B true MX347570B (es) 2017-05-02

Family

ID=48429067

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014005765A MX347570B (es) 2011-11-15 2012-11-15 Compuestos triciclicos, composiciones que los comprenden y usos de los mismos.

Country Status (24)

Country Link
US (1) US9447040B2 (es)
EP (1) EP2802320B1 (es)
JP (1) JP6087367B2 (es)
KR (1) KR101986272B1 (es)
CN (1) CN104010636B (es)
AU (1) AU2012338362B2 (es)
BR (1) BR112014011641B1 (es)
CA (1) CA2855759C (es)
CL (1) CL2014001278A1 (es)
CO (1) CO7020909A2 (es)
DK (1) DK2802320T3 (es)
ES (1) ES2729713T3 (es)
HR (1) HRP20190927T1 (es)
HU (1) HUE043827T2 (es)
IN (1) IN2014CN03610A (es)
MX (1) MX347570B (es)
PE (1) PE20141940A1 (es)
PL (1) PL2802320T3 (es)
PT (1) PT2802320T (es)
RU (1) RU2624446C9 (es)
SG (1) SG11201402258UA (es)
SI (1) SI2802320T1 (es)
WO (1) WO2013072915A1 (es)
ZA (1) ZA201404065B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016020919A1 (en) 2014-08-07 2016-02-11 Raziel Therapeutics Ltd. Compositions comprising tricyclic compounds, and uses thereof
US10632102B2 (en) * 2015-06-15 2020-04-28 Raziel Therapeutics Ltd Carbazole derivatives for the treatment of fibrotic diseases and related symptoms, and conditions thereof
JP2023503769A (ja) * 2019-09-15 2023-02-01 ラジエル セラピューティクス エルティーディー． 固形腫瘍の処置のための組成物
AU2021213469A1 (en) * 2020-01-28 2022-08-25 Raziel Therapeutics Ltd. Compositions for the treatment of angiolipoma
WO2022058792A1 (en) * 2020-09-16 2022-03-24 Raziel Therapeutics Ltd. Compositions for the treatment of fat related conditions and disorders
US20230355584A1 (en) * 2020-09-16 2023-11-09 Raziel Therapeutics Ltd. Compositions and methods for the treatment of lipid-related disorders
AU2022270984A1 (en) * 2021-05-06 2023-11-23 Raziel Therapeutics Ltd. Crystalline carbazole derivative
AU2022320006A1 (en) * 2021-07-28 2024-02-22 Raziel Therapeutics Ltd. Compositions and methods for treating lipoma pain
CN115073374B (zh) * 2022-06-14 2023-10-27 五邑大学 一种α-葡萄糖苷酶抑制剂及其制备方法和应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2590125A (en) * 1952-03-25 Quaternary-ammonium alkyl
US2676966A (en) * 1951-04-04 1954-04-27 Searle & Co Quaternary salts of 9-carbazolealkylamines and 10-acridanalkylamines and methods forpreparing same
US2676971A (en) * 1951-04-21 1954-04-27 Searle & Co Quaternary ammonium derivatives of aminoalkylxanthenes and aminoalkylthiaxanthenes
US2930798A (en) * 1956-08-03 1960-03-29 Clin Byla Ets 3-alkanoyl 1-tertiary-amino-alkyl indol oximes and production thereof
GB832568A (en) * 1956-08-03 1960-04-13 Clin Byla Ets Heterocyclic compounds and production thereof
FR1186832A (fr) * 1956-08-03 1959-09-02 Etablissements Clin-Byla Composés hétérocycliques dérivés du pyrrol et des benzopyrrols et leur fabrication
GB866418A (en) * 1958-01-25 1961-04-26 Bayer Ag Phenoxazine derivatives
US3836587A (en) * 1969-11-17 1974-09-17 American Cyanamid Co Organo phosphonium salts
AR205331A1 (es) * 1972-07-24 1976-04-30 Hoffmann La Roche Procedimiento para la preparacion de carbazoles
FR2691459B1 (fr) * 1992-05-25 1995-06-09 Adir Nouveaux derives de la phenothiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
AU5644396A (en) 1995-05-05 1996-11-21 Novo Nordisk A/S Novel heterocyclic chemistry
US6440961B1 (en) 1997-10-27 2002-08-27 Dr. Reddy's Research Foundation Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
EP1094063A1 (en) 1999-10-18 2001-04-25 Applied Research Systems ARS Holding N.V. 9-(Piperazinylalkyl)carbazoles as Bax-modulators
GB9925880D0 (en) 1999-11-01 1999-12-29 British Tech Group Int B-Carboline derivatives
DE60218155D1 (de) 2001-03-28 2007-03-29 Lilly Co Eli Substituierte carbazole als inhibitoren von spla2
WO2003027084A1 (en) 2001-09-25 2003-04-03 Dr. Reddy's Laboratories Ltd. Improved process for the preparation of optically active phenoxazine derivatives as antidiabetic agents
US7428091B2 (en) * 2004-11-15 2008-09-23 Gentex Corporation Electrochromic compounds and associated media and devices
WO2007079239A2 (en) 2005-12-30 2007-07-12 Acadia Pharmaceuticals Inc. Bicyclic nitrogen compounds as modulators of ghrelin receptor and uses thereof
US20090317372A1 (en) 2008-06-20 2009-12-24 Zoltan Kiss Small molecules for the reduction of high blood glucose level
UA107652C2 (en) * 2008-10-06 2015-02-10 Incuron Llc Carbazole compounds and therapeutic uses of the compounds
US8362277B2 (en) * 2009-01-09 2013-01-29 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
AU2010203356B2 (en) 2009-01-09 2015-11-26 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
DK2590647T3 (en) * 2010-07-07 2018-02-12 Univ Texas Pro-neurogenic compounds

Also Published As

Publication number Publication date
SG11201402258UA (en) 2014-06-27
CA2855759C (en) 2020-03-10
AU2012338362B2 (en) 2017-05-18
CO7020909A2 (es) 2014-08-11
JP6087367B2 (ja) 2017-03-01
HUE043827T2 (hu) 2019-09-30
JP2014533264A (ja) 2014-12-11
IN2014CN03610A (es) 2015-10-09
MX2014005765A (es) 2015-09-23
BR112014011641A2 (pt) 2017-05-02
CN104010636B (zh) 2017-04-12
RU2014119711A (ru) 2015-12-27
EP2802320A4 (en) 2015-08-12
HRP20190927T1 (hr) 2019-08-23
BR112014011641B1 (pt) 2020-10-27
EP2802320A1 (en) 2014-11-19
CA2855759A1 (en) 2013-05-23
KR101986272B1 (ko) 2019-06-05
ES2729713T3 (es) 2019-11-05
DK2802320T3 (da) 2019-05-27
CL2014001278A1 (es) 2014-12-26
RU2624446C9 (ru) 2018-04-04
US20140329877A1 (en) 2014-11-06
PL2802320T3 (pl) 2019-09-30
ZA201404065B (en) 2015-11-25
US9447040B2 (en) 2016-09-20
PT2802320T (pt) 2019-06-17
KR20140099492A (ko) 2014-08-12
CN104010636A (zh) 2014-08-27
RU2624446C2 (ru) 2017-07-04
AU2012338362A1 (en) 2014-05-29
WO2013072915A1 (en) 2013-05-23
EP2802320B1 (en) 2019-02-20
PE20141940A1 (es) 2014-12-18
SI2802320T1 (sl) 2019-08-30

Similar Documents

Publication Publication Date Title
MX347570B (es) Compuestos triciclicos, composiciones que los comprenden y usos de los mismos.
PH12015501393A1 (en) Pesticidal compositions and processes related thereto
PH12015501392A1 (en) Pesticidal compositions and processes related thereto
PH12014502398B1 (en) Pesticidal compositions and processes related thereto
NZ709392A (en) Synergistic bacterial compositions and methods of production and use thereof
EP2560660A4 (en) THERAPIES BASED ON CHEMOSOUS RECEPTOR LIGANDS
PH12014502704B1 (en) Compounds and compositions for modulating egfr activity
CR20120202A (es) Métodos y composiciones para tratar cáncer
MX2016016800A (es) Metodos para el tratamiento del sobrepeso o la obesidad.
PH12015501394A1 (en) Pesticidal compositions and processes related thereto
TR201813877T4 (tr) Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
NZ708727A (en) Conjugate compounds
IN2012DN03217A (es)
MX346665B (es) Composiciones pesticidas y procedimientos relacionados con estas.
GEP20186899B (en) 6 - alkynyl pyridines as smac mimetics
MX2011009780A (es) Pirimidinas sustituidas para el tratamiento del cancer.
MX2013009252A (es) Composiciones y procesos relacionados con los mismos plaguicidas.
SG179161A1 (en) Tricyclic compounds and pharmaceutical uses thereof
AP2011005978A0 (en) 2, 4 diaminopyrimidines for the treatment of diseases characterised by excessive or abnormal cell proliferation.
MY165075A (en) Pharmaceutical composition comprising fimasartan and hydrochlorothiazide
UY34575A (es) Composiciones y métodos para el tratamiento de diabetes y/u obesidad
EP2576536A4 (en) INHIBITORS OF HEMATOPOIETIC PROSTAGLANDIN D2 SYNTHASE
EP2585067A4 (en) COMPOUND FOR THE TREATMENT OF ENTEROVIRUS
MX361233B (es) Inhibidores de hsp90 c-terminales.
MX363385B (es) Métodos para el tratamiento de enfermedad de células falciformes y otras condiciones inflamatorias.

Legal Events

Date Code Title Description
FG Grant or registration